OGI Stock Analysis: Buy, Sell, or Hold?
OGI - Organigram Global Inc. Common Shares
$0.95
-0.01 (-0.94%)
▼
5d:
-7.67%
30d:
-15.84%
90d:
-30.07%
HOLD
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When OGI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OGI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: OGI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: OGI is currently trading at $0.95, which is considered oversold relative to its 30-day fair value range of $1.01 to $1.12. From a valuation perspective, the stock is trading at a discount (Forward PE: 43.2) compared to its historical average (63.1). Remarkably, the market is currently pricing in an annual earnings decline of 11.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, OGI is in a strong downtrend. The price is currently testing key support at $1.06. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.80 (+825.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OGI is in a strong downtrend. The price is currently testing key support at $1.06. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.80 (+825.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.01 -
$1.12
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 825.3% below Wall St target ($8.80)
- CAUTION: Recommendation downgraded due to -7.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.01 -
$1.12
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.16
(16.5%)
Support & Resistance Levels
Support Level
$1.06
Resistance Level
$1.21
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
43.23
Wall Street Target
$8.80
(+825.3%)
Revenue Growth (YoY)
-8.9%
Profit Margin
-9.2%
Valuation Discount vs History
-11.9% cheaper
PE vs Historical
43.2 vs 63.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.9%
(market-implied from PE analysis)
1-Year Target
$0.86
(-10%)
2-Year Target
$0.77
(-19%)
3-Year Target
$0.69
(-27%)
3-Yr Target (if PE normalizes)
(PE: 43→63)
$1.01
(+6%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 43.2, Growth: -66.7%)
$0.69
(+-27%)
Base:
(SPY PE: 21.8, Growth: -66.7%)
$0.35
(-63%)
Bear:
(PE: 18.5, Growth: -66.7%)
$0.30
(-69%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 43.2 to 63.1
Stabilization Target:
$1.39
(+46.0%)
PE Expansion Potential:
+46.0%
Share & Embed Analysis
Last updated: June 24, 2026 1:04 AM ET
Data refreshes hourly during market hours. Next update: 2:04 AM
Data refreshes hourly during market hours. Next update: 2:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OGI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
